STAAR Surgical Company
STAA · NASDAQ
12/27/2024 | 12/29/2023 | 12/30/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.30 | -1.51 | 0.99 | 0.52 |
| FCF Yield | -0.64% | -0.24% | 0.76% | 0.70% |
| EV / EBITDA | -189.49 | 41.15 | 47.07 | 112.02 |
| Quality | ||||
| ROIC | -6.35% | 4.16% | 10.29% | 9.75% |
| Gross Margin | 76.32% | 78.36% | 78.55% | 77.51% |
| Cash Conversion Ratio | -0.78 | 0.68 | 0.92 | 1.60 |
| Growth | ||||
| Revenue 3-Year CAGR | 3.35% | 11.84% | 20.27% | 15.34% |
| Free Cash Flow Growth | -113.38% | -120.41% | -41.92% | 141.63% |
| Safety | ||||
| Net Debt / EBITDA | 18.43 | -4.43 | -1.15 | -4.53 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 877.34 |
| Efficiency | ||||
| Inventory Turnover | 1.72 | 1.99 | 2.53 | 3.00 |
| Cash Conversion Cycle | 222.81 | 223.79 | 159.97 | 134.12 |